Abstract:Objectives Tissue inhibitor of metalloproteinases-1 (TIMP-1) is considered to play a key role in the development of pulmonary arterial hypertension (PAH). However, the molecular regulatory mechanisms of TIMP-1 in the pulmonary arteries were not very clear, especially in the human pulmonary arterial smooth muscle cells (HPASMCs). This study try to investigate the signalling pathway involved in the regulation of TIMP-1 in HPASMCs stimulated with transforming growth factor (TGF)-β1. Methods Cultured HPASMCs were incubated with different concentrations of TGF-β1 (0, 2.5, 5, 10, 20 or 40 ng/ml) for 24 h, or with 10 ng/ml TGF-β1 for different time (1, 4, 8, 12, 24 or 48 h). Western blot and real-time PCR were employed to detect the protein and mRNA expression of TIMP-1 in HPASMCs, and enzyme-linked immuno sorbent assay (ELISA) was used to detect the secretion of TIMP-1 in the culture medium. Then, the activities of three mitogen-activated protein kinases (MAPK), including extracellular signal-regulated kinase 1/2 (ERK1/2), p38 and c-Jun NH2-terminal kinase (JNK), were respectively inhibited with their specific inhibitors, U0126, SB202190 and SP600125. The protein and mRNA of TIMP-1 were also detected to help distinguishing that which kinase was involved in the regulation of TIMP-1 in HPASMCs induced by TGF-β1. Besides this, mithramycin, a specific inhibitor of Sp1 transcription factor, and curcumin, a specific inhibitor of activator protein-1 (AP-1), were used to block the DNA-binding activity of Sp1 or AP-1 respectively. And electrophoretic mobility shift assay (EMSA), Western blot and real-time PCR were carried out to help confirming that which transcription factor was involved in the regulation of TIMP-1 in HPASMCs. Results Western blot, real-time PCR and ELISA analysis showed that TGF-β1 could time- and dose-dependently enhance the expression and secretion of TIMP-1. Furthermore, TGF-β1 could phosphorylate two kinases of MAPK, ERK1/2 and p38, but not JNK, and the phosphorylation of p38 was weaker compared with ERK1/2. Of these kinases, only the inhibition of ERK 1/2 by U0126 effectively blocked the TGF-β1-induced expression of TIMP-1. Mithramycin also significantly reduced the expression of TIMP-1 via blocking the DNA-binding activity of Sp1. However, the inhibition of AP-1 by curcumin couldn't achieve this result. Additionally, the results of EMSA showed that TGF-β1 could up-regulate the DNA-binding activity of Sp1, and that U0126 and mithramycin could effectively suppressed this activation in a dose-dependent manner. Conclusions TGF-β1 could time- and dose-dependently stimulate the expression and secretion of TIMP-1 in HPASMCs, and ERK1/2 and Sp1 signalling pathways might be involved in these activities.

Cyclic guanosine monophosphate inhibits the palmitoylation of LETM1 and downregulates the activity of AKT in human pulmonary artery smooth muscle cells

Capping Protein Gelsolin-Like As A Therapeutic Target to Prevent Hypoxic Pulmonary Hypertension

ACTIVATION OF ERK 1/2 AND SP1 MAY CONTRIBUTE TO THE EXPRESSION OF TISSUE INHIBITOR OF METALLOPROTEINASE-1 INDUCED BY TRANSFORMING GROWTH FACTOR-β1 IN HUMAN PULMONARY ARTERIAL SMOOTH MUSCLE CELLS

Involvement of CapG in Proliferation and Apoptosis of Pulmonary Arterial Smooth Muscle Cells and in Hypoxia-Induced Pulmonary Hypertension Rat Model

CPT1 regulates the proliferation of pulmonary artery smooth muscle cells through the AMPK-p53-p21 pathway in pulmonary arterial hypertension

PARM1 Drives Smooth Muscle Cell Proliferation in Pulmonary Arterial Hypertension via AKT/FOXO3A Axis

Identifying Potential Mitochondrial Proteome Signatures Associated with the Pathogenesis of Pulmonary Arterial Hypertension in the Rat Model

T18/S19 diphosphorylation of myosin regulatory light chain impairs pulmonary artery relaxation in monocrotaline-induced pulmonary hypertensive rats

NCAPG Promotes Pulmonary Artery Smooth Muscle Cell Proliferation as a Promising Therapeutic Target of Idiopathic Pulmonary Hypertension: Bioinformatics Analysis and Experiment Verification

PPARδ Agonist GW501516 Inhibits PDGF-stimulated Pulmonary Arterial Smooth Muscle Cell Function Related to Pathological Vascular Remodeling.

ERK/Drp1‐dependent mitochondrial fission contributes to HMGB1‐induced autophagy in pulmonary arterial hypertension

Inhibition of Ubiquitin Proteasome Function Prevents Monocrotaline-Induced Pulmonary Arterial Remodeling

Abstract 12004: Mitochondrial Fission Mediator MiD49 Regulates Proliferation via MYO1C in Pulmonary Arterial Hypertension

Internet Technology: Resources for Perinatal Nurses

Enhancing Gpx1 Palmitoylation to Inhibit Angiogenesis by Targeting PPT1

Akt-Dependent Glycolysis-Driven Lipogenesis Supports Proliferation and Survival of Human Pulmonary Arterial Smooth Muscle Cells in Pulmonary Hypertension

Abstract 14485: LDHA-Lactate Promotes Smooth Muscle Remodeling and Pulmonary Hypertension Through Lactylation of TOP1 and EMILIN1

Adenosine monophosphate, one metabolite from lower respiratory tract, promotes the progression of pulmonary arterial hypertension through the PI3K/AKT signaling pathway in pediatric with congenital heart disease

Activation of AMPK Prevents Monocrotaline-Induced Extracellular Matrix Remodeling of Pulmonary Artery.

Targeting ADORA-PDE10 cAMP Microdomain: A Novel Therapeutic Approach for Pulmonary Hypertension

Abstract 17836: ATP Citrate Lyase Coordinates Lipid Synthesis and Expression Cell Cycle Regulating Genes to Promote Vascular Remodeling in Pulmonary Arterial Hypertension